Lantern Pharma Reports Promising Phase 1a Results for LP‑184, Showing Durable Control in Tough Cancers
Lantern Pharma’s investigational drug LP‑184 showed durable disease control in a Phase 1a trial of 63 heavily pre‑treated advanced cancer patients, meeting all safety and tolerability endpoints. The study established a recommended Phase 2 dose of 0.39 mg/kg, with a disease‑control rate of ~54% at or above therapeutic doses. Patients with DNA‑damage‑repair mutations, including NSCLC and thymic carcinoma, remain on treatment for 12–23+ months, showing meaningful tumor reductions. These results support Lantern’s precision‑oncology strategy and plans for multiple biomarker‑guided Phase 1b/2 trials across several tumor types. 
Lantern Pharma Reports Promising Phase 1a Results for LP‑184, Showing Durable Control in Tough Cancers